MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2017 International Congress

    Displacement of deep brain stimulation (DBS) lead location after implantation: Preliminary result of a study comparing early Vs late CT findings

    X.-L. Zhu, C. Lau, C.-M. Cheung, D. Chan, A. Chan, V. Mok, J. Yeung, W. Poon (Hong Kong, China)

    Objective: To investigate the cause and to minimize the lead location displacement after DBS implantation Background: Precise targeting is the key towards successful deep brain stimulation…
  • 2017 International Congress

    Analysis of the exclusion causes for deep brain stimulation in Parkinson’s Disease Center in southern Taiwan

    Y.-F. CHEN, Y.-F. CHEN, C.-C. CHANG, Y. LI, Y.-Y. CHANG (Kaohsiung, Taiwan)

    Objective: To analyze why patients with Parkinson’s disease (PD) were excluded from candidate selection for subthalamic deep brain stimulation. Background: Subthalamic deep brain stimulation (STN-DBS)…
  • 2017 International Congress

    The non-motor symptoms in Parkinsons’s disease patients treated with STN DBS: the follow up study

    M. Mencinger, M. Červek, T. Rus, G. Jakob, D. Georgiev, D. Flisar, R. Rajnar, M. Benedičič, K. Boetzel, J. Mehrkens, Z. Pirtošek, M. Trošt (Ljubljana, Slovenia)

    Objective: The aim of the study was to follow-up the effect of STN DBS on motor and non-motor symptoms in aPD.  Background: A comprehensive assessment…
  • 2017 International Congress

    Tear tumor necrosis factor-alpha levels in patients with Parkinson’s disease: The effect of deep brain stimulation

    B. Kocer, S. Comoglu, H. Guven, M. Acar, G. Ozturk (Ankara, Turkey)

    Objective: To evaluate tear tumor necrosis factor-alpha (TNF-α) levels in samples of two Parkinson’s disease (PD) patients treated with subthalamic nucleus (STN) deep brain stimulation…
  • 2017 International Congress

    An MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia

    M. Stacy, R. Kurlan, J. Burke, S. Siegert, G. Liang, C. O'Brien (Durham, NC, USA)

    Objective: To establish a minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score change using data from randomized, double-blind, placebo…
  • 2017 International Congress

    An Unusual Cause of Rhabdomyolysis in Parkinson’s disease

    Y. Pitakpatapee, C. Satukijchai, P. Srivanitchapoom (Bangkok, Thailand)

    Objective: To describe an unusual cause of rhabdomyolysis in patient with advanced Parkinson’s disease (PD) treated with levodopa. Background: Rhabdomyolysis is a serious and life-threatening…
  • 2017 International Congress

    Association analysis of single nucleotide polymorphisms near the DYT3 locus to dystonic symptoms in X-linked dystonia-parkinsonism

    G. Saranza, D. Sumalapao, A. Domingo, P. Pasco, R.D. Jamora, L. Lee, A. Westenberger, C. Klein (Manila, Philippines)

    Objective: We aimed to elucidatewhether single nucleotide polymorphisms within the XDP locus affect the phenotypic expression of XDP.  Background: X-linked Dystonia-Parkinsonism (XDP, DYT3, Lubag Disease,…
  • 2017 International Congress

    Rice bran extract against animal model of Huntington’s disease: Possible role of neurotransmitters

    P. Kumar, N. Kaur (Bathinda, Punjab, India)

    Objective: The present study has been designed to explore the effect of rice bran extract against 3-NP induced neurotoxicity in rats.  Background: Huntington’s disease (HD)…
  • 2017 International Congress

    A modified model for prediction of Huntington disease age of onset based on length of CAG repeat expansion

    Y. Seliverstov, E. Shulgina, S. Illarioshkin, M. Belyaev (Moscow, Russian Federation)

    Objective: We aimed to search for a possibility to modify Langbehn et al. model (LanM) for prediction of Huntington disease (HD) age of onset based on length of CAG…
  • 2017 International Congress

    Efficacy, Safety, and Tolerability of Pridopidine in Huntington Disease (HD): Results From the Phase II Dose-Ranging Study, Pride-HD

    R. Reilmann, A. McGarry, G. Landwehrmeyer, K. Kieburtz, I. Grachev, E. Eyal, J. Savola, B. Borowsky, S. Papapetropoulos, M. Hayden (Münster, Germany)

    Objective: To assess efficacy, safety, and tolerability of multiple doses of pridopidine in HD patients (pts) with signs of motor dysfunction. Background: Prior trials suggested…
  • « Previous Page
  • 1
  • …
  • 59
  • 60
  • 61
  • 62
  • 63
  • …
  • 155
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley